The estimated Net Worth of William A. Nuerge is at least $738 Mille dollars as of 4 May 2012. William Nuerge owns over 15,000 units of Supernus Pharmaceuticals Inc stock worth over $738,150 and over the last 13 years William sold SUPN stock worth over $0.
William has made over 1 trades of the Supernus Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently William bought 15,000 units of SUPN stock worth $75,000 on 4 May 2012.
The largest trade William's ever made was buying 15,000 units of Supernus Pharmaceuticals Inc stock on 4 May 2012 worth over $75,000. On average, William trades about 1,875 units every 0 days since 2012. As of 4 May 2012 William still owns at least 23,750 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of William Nuerge stock trades at the bottom of the page.
William's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE, MD, 20850.
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell e Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: